SKIP TO CONTENT
Johns Hopkins
  • Home
  • About
  • News
  • Contact
  • Login

    • FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.

    LEARN MORE
    SEE ALL NEWS
    Recent Posts
    After a year of turmoil, cancer researchers see promising signs for mRNA vaccines AI and Mammograms Single Nutrient Fuels Cancer-Fighting Power of T Cells Alcohol and Cancer Risk Colon Cancer Screening: What You Need to Know Detecting Early-Stage Cancers with a New Blood Test Measuring Epigenetic Instability Oral Bacterium May Promote Breast Cancer Development and Spread Extra Copies of Chromosome 1q May Drive Pancreatic Cancer How Bacteria May Promote Breast Cancer
    Johns Hopkins

    2026 © The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
    Terms of Use Privacy Statement

    LinkedIn
    Back to top